Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS)
- 5 July 2023
- journal article
- review article
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (10) , 1799-1804
Abstract
Denosumab is a human monoclonal antibody indicated for patients with osteoporosis and a high risk of fractures. It targets RANKL, the receptor activator of NF-κB (RANK) ligand, blocking RANKL-RANK interaction and leading to rapid osteoclast-mediated bone resorption inhibition. But RANK is widely expressed in neurons, microglia, and astrocytes. RANKL/RANK/NF-κB system can play an important role in the neuroinflammatory response, depressive behavior, memory impairments, and neurotrophism. We present two well-documented case reports of recurrent neuropsychiatric manifestations in patients treated with denosumab and a descriptive review of similar cases reported to the Food and Drug Administration Adverse Event Reporting System (FAERS) database between 2012 and 2022. Only those reported by healthcare professionals, coding denosumab as the only suspected drug, were retained. An 81-year-old woman with pre-existing mild cognitive impairment suffered two acute confusional episodes and another 81-year-old woman with depression in remission suffered two depressive recurrences with anxiety and psychomotor inhibition, in both cases following sequential administrations of denosumab without underlying calcium/phosphate imbalance. Scores on Naranjo Adverse Drug Reaction Probability Scale were 6 and 7, respectively, suggesting a probable causal relationship. Of the 91,151 cases with denosumab exposure reported to FAERS, 5.7% were related to psychiatric/neurological disorders and 23.8% of these corresponded to cognitive impairment, depressive/mood disturbances, or psychomotor retardation. Denosumab may cause transient but severe neuropsychiatric symptoms by several mechanisms involving RANKL blockade and subsequent immuno-inflammatory changes, at least in subjects with pre-existing neurobiological vulnerability. We recommend caution and careful monitoring of these patients following denosumab administrations.Keywords
This publication has 17 references indexed in Scilit:
- OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in miceProceedings of the National Academy of Sciences, 2014
- Bipolar Depressive Recurrence Following Treatment with the Human Monoclonal Antibody Denosumab: A Case ReportBiological Psychiatry, 2013
- Denosumab: mechanism of action and clinical outcomesInternational Journal Of Clinical Practice, 2012
- Neuroplastic changes in depression: A role for the immune systemPsychoneuroendocrinology, 2012
- Regulation of neural process growth, elaboration and structural plasticity by NF-κBTrends in Neurosciences, 2011
- Immune system to brain signaling: Neuropsychopharmacological implicationsPharmacology & Therapeutics, 2011
- Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behaviorProceedings of the National Academy of Sciences, 2010
- Unravelling the pathophysiology of delirium: A focus on the role of aberrant stress responsesJournal of Psychosomatic Research, 2008
- Increased Stress-Induced Inflammatory Responses in Male Patients With Major Depression and Increased Early Life StressAmerican Journal of Psychiatry, 2006
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981